Table 2.

Major trials of antiresorptive agents for prevention of aibl in postmenopausal women with breast cancer.

Antiresorptive agent (Trial)	N	BMD data, na	Dose	Treatment duration	Follow-up, months	Mean BMD increase from baseline, %
						LS	TH
Zoledronate	1,065	1,065	4 mg q6mo	5 yr	36b	4.39	1.9
(ZO-FAST) [69]
Zoledronate	602	602	4 mg q6mo	5 yr	61	6.19	2.57
(Z-FAST) [81]
Zoledronate	558	395	4 mg q6mo	5 yr	24	4.94	1.22
(N03CC) [82]
Zoledronate	527	527	4 mg q6mo	5 yr	36	5.98	NR
(E-ZO-FAST) [83]
Denosumab	252	252	60 mg q6mo	2 yr	24	6.2c	3.7c
(HALT-BC) [84]	3420	3420	60 mg q 6mo	3 yr	36	10,2	7,92
Denosumab						Fracture reduction:
(ABCSG-18) [92], [93]
						OR 0.53 (CI 0.333–0.85, p=0.009)
Risedronate	154	111	35 mg/wk	2 yr	24	2.2	1.8
(SABRE) [85]
Risedronate [86]	87	87	35 mg/wk	2 yr	24	0.4	0.9
Clodronate [87]	61	61	1,600 mg/day	3 yr	60	–1.0	–0.1
Risedronate (IBIS II- Stratum II) [88]	260	150	35 mg/wk	3 yr	36	1.1	-0.7
	1410	903	35 mg/wk	3 yr	36	1,1%	-0,7%
	213	132	35 mg/wk	2 yr	24	5,7%	1,6%
Risedronate
(IBIS II) [106]
Risedronate
(ARBI) [106]
Ibandronate	131	50	150 mg/mo	5 yr	60	5.01%	1.19%
(ARIBON) [89]
Risedronate [90]	118	11	35 mg/wk	1 yr	12	4.1	1.8
	303	303	70 mg/wk	3 yr	36	15.6 (osteoporosic)	5.6 (osteoporotic)
Alendronate
(BATMAN)[109].						6.3 (osteopenic)	6.3 (osteopenic)

Abbreviations: AI, aromatase inhibitor; AIBL, aromatase inhibitor-associated bone loss; BMD, bone mineral density; LS, lumbar spine; mo, months; NR, not reported; TH, total hip; yr, years.

^aNumber of patients randomized to bisphosphonate vs placebo and evaluable for BMD at the reported timepoint;

^bBMD data available for 36 months’ follow-up; disease recurrence outcomes available for 48 months’ follow-up.

^cEstimates based on published graph.